ASCO 2017 - Chicago - Chronic Myeloid Leukemia
GENERAL INFORMATION
ASCO American Society of Clinical Oncology - June 3 - June 6, 2017- McCormick Place, Chicago, Illinois
ASCO American Society of Clinical Oncology - June 3 - June 6, 2017- McCormick Place, Chicago, Illinois
SOME INTERESTING ABSTRACTS ABOUT CML
Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).
Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective
Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.
The OMNI patient registry: A prospective observational registry to assess vascular safety in patients with CML and Ph+ ALL treated with ponatinib.
Patients with myeloproliferative neoplasms (MPN) who later develop ph+ chronic myelogenous leukemia (CML): A case series.
Musculoskeletal symptoms in chronic myeloid leukemia patients after stopping tyrosine kinase inhibitors.
Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era.
Generic imatinib therapy among Jordanians: An observational assessment of safety and efficacy in routine clinical practice.
Comparison of digital PCR with real-time PCR calibrated to the International Scale for BCR-ABL monitoring.
Early results of lower-dose dasatinib, 50 mg daily, in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Four-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts). | 2017 ASCO Annual Meeting Abstracts
Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.
Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
The effect of aspirin and anticoagulation on tyrosine kinase inhibitors induced thrombotic events in chronic myeloid leukemia: A retrospective cohort.
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience.
The emotional journey among caregivers of patients with leukemia: The caregivers' perspective using social media listening.
Pharmaceutical industry payments and oncologist drug selection.
FDA analysis of MRD data in hematologic malignancy applications.
Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
ESKAPEade in hematological malignancies: Dare to review!
Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.
Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status
Real-world outcomes of ponatinib in treatment of advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure.
Incidence and survival trends of cancers diagnosed in young adults (20-39 years): A population-based study
Sexual activity and function in male cancer patients receiving targeted an immune therapies
Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).
Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective
Bosutinib (BOS) versus imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial.
The OMNI patient registry: A prospective observational registry to assess vascular safety in patients with CML and Ph+ ALL treated with ponatinib.
Patients with myeloproliferative neoplasms (MPN) who later develop ph+ chronic myelogenous leukemia (CML): A case series.
Musculoskeletal symptoms in chronic myeloid leukemia patients after stopping tyrosine kinase inhibitors.
Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era.
Generic imatinib therapy among Jordanians: An observational assessment of safety and efficacy in routine clinical practice.
Comparison of digital PCR with real-time PCR calibrated to the International Scale for BCR-ABL monitoring.
Early results of lower-dose dasatinib, 50 mg daily, in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Four-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts). | 2017 ASCO Annual Meeting Abstracts
Impact of early landmark responses with ponatinib on 4-yr outcomes in CP-CML patients (pts) in PACE, a pivotal phase II trial.
Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
The effect of aspirin and anticoagulation on tyrosine kinase inhibitors induced thrombotic events in chronic myeloid leukemia: A retrospective cohort.
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
Long term efficacy of nilotinib as front- and second-line therapy in Bosnia and Herzegovina: Real life experience.
The emotional journey among caregivers of patients with leukemia: The caregivers' perspective using social media listening.
Pharmaceutical industry payments and oncologist drug selection.
FDA analysis of MRD data in hematologic malignancy applications.
Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
ESKAPEade in hematological malignancies: Dare to review!
Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.
Does access to cancer drugs relate to survival benefit? A European study in countries with different economic status
Real-world outcomes of ponatinib in treatment of advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure.
Incidence and survival trends of cancers diagnosed in young adults (20-39 years): A population-based study
Sexual activity and function in male cancer patients receiving targeted an immune therapies
